1. Propetolerance after pediatric liver transplantation
- Author
-
Christophe Bourdeaux, Catherine De Magnee, M. Janssen, Raymond Reding, Fabio Fusaro, Aurore Pire, Françoise Smets, Etienne Sokal, and Xavier Stéphenne
- Subjects
Graft Rejection ,medicine.medical_specialty ,Daclizumab ,Adolescent ,Recombinant Fusion Proteins ,medicine.medical_treatment ,Liver transplantation ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Tacrolimus ,Basiliximab ,Steroid avoidance ,Internal medicine ,Immune Tolerance ,medicine ,Humans ,Child ,Transplantation ,Graft acceptance ,business.industry ,Graft Survival ,Age Factors ,Antibodies, Monoclonal ,Infant ,Immunosuppression ,Liver Transplantation ,Surgery ,Calcineurin ,Regimen ,Treatment Outcome ,surgical procedures, operative ,Child, Preschool ,Immunoglobulin G ,Pediatrics, Perinatology and Child Health ,Toxicity ,Steroids ,business ,Immunosuppressive Agents - Abstract
pT, under mono- and infratherapeutic calcineurin inhibition, may constitute an optimal condition combining graft acceptance with low IS load and minimal IS-related toxicity. We reviewed 171 pediatric (
- Published
- 2012